SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Results of Operations and Financial ConditionItem 9.01 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 7, 2018, Second Sight Medical Products, Inc. (the “Company”) announced financial results for the three-month period and six-month period ended June 30, 2018 in the earnings release attached hereto as Exhibit99.1.
The information in this Item 9.01 including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS
SECOND SIGHT MEDICAL PRODUCTS INC ExhibitEX-99.1 2 ex_120886.htm EXHIBIT 99.1 ex_120886.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Reports Second Quarter 2018 Financial Results — Achieves program milestones as Orion clinical and R&D activities advance — — Received FDA approval to enroll 6th patient at Baylor — Los Angeles,…To view the full exhibit click here
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.